Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the discovery, development, manufacturing, and marketing of pharmaceutical products. The company operates in approximately 170 countries and focuses on providing innovative treatments for diabetes, obesity, cardiovascular diseases, and rare disorders. Its product portfolio includes GLP-1 receptor agonists, insulins, and therapies for rare diseases such as haemophilia and growth hormone deficiencies.
-
Diabetes and Obesity Care - Develops and markets therapies for diabetes, obesity, and cardiovascular diseases, including GLP-1 receptor agonists like Ozempic®, Wegovy®, Saxenda®, and Rybelsus®, as well as modern and human insulins.
- GLP-1 Products: Includes Ozempic®, Wegovy®, Saxenda®, Rybelsus®, and Victoza®.
- Insulins: Includes Tresiba®, Xultophy®, Levemir®, NovoMix®, and NovoRapid®.
-
Rare Disease - Focuses on treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapies. Key products include NovoSeven® for haemophilia and growth hormone therapies.
You might also like
- Given the competitive landscape and recent pricing dynamics, can you provide more granularity on how the net price evolution for Wegovy in the U.S. aligns with your expectations, and how pricing movements in certain channels might impact your strategy?
- With the expected increase in selling and distribution spend later in the year tied to supply availabilities and R&D readouts, what specific factors are gating this inflection in spend, and how does this align with your capacity to meet the anticipated demand?
- Considering concerns about central nervous system penetration and potential psychiatric side effects with CB1 inverse agonists like rimonabant, what underpins your confidence that your lead asset doesn't significantly penetrate the brain, and how are you managing these risks in clinical development?
- Acknowledging that the obesity market is likely to evolve significantly by 2030 with new competitors and products, how do you foresee the market dynamics changing over time, and what assumptions are you making regarding your own portfolio evolution and the efforts of others?
- As you advance CagriSema with potentially higher efficacy, should we anticipate a significant shift of patients from semaglutide to CagriSema, and how are you addressing potential manufacturing challenges given external production of cagrilintide and capacity constraints?
Research analysts who have asked questions during NOVO NORDISK A S earnings calls.
Peter Verdult
Citigroup Inc.
5 questions for NVO
Richard Vosser
JPMorgan Chase & Co.
5 questions for NVO
James Quigley
Goldman Sachs
4 questions for NVO
Sachin Jain
Bank of America
4 questions for NVO
Jo Walton
UBS
3 questions for NVO
Michael Nedelcovych
TD Cowen
3 questions for NVO
Simon Baker
Redburn Atlantic
3 questions for NVO
Callum Morris
Berenberg
2 questions for NVO
Evan Seigerman
BMO Capital Markets
2 questions for NVO
Harry Sephton
UBS
2 questions for NVO
Martin Parkhoi
SEB
2 questions for NVO
Michael Leuchten
Jefferies
2 questions for NVO
Thibault Boutherin
Morgan Stanley
2 questions for NVO
Yihan Li
Barclays
2 questions for NVO
Emily Field
Barclays
1 question for NVO
Emmanuel Papadakis
Deutsche Bank
1 question for NVO
James Creedy
Goldman Sachs Group Inc.
1 question for NVO
Laura Hindley
Berenberg Bank
1 question for NVO
Michael Novod
Nordea
1 question for NVO
Peter Welford
Jefferies
1 question for NVO
Rajesh Kumar
HSBC
1 question for NVO
Richard Parkes
BNP Paribas Exane
1 question for NVO
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Catalent, Inc. | 2024 | Catalent, Inc. was acquired via a merger that included the purchase of three manufacturing sites in Italy, Belgium, and Indiana for an upfront payment of $11 billion USD; the debt-financed deal strategically enhances Novo Nordisk's capacity in diabetes and obesity treatments and was completed on December 18, 2024. |
Cardior Pharmaceuticals GmbH | 2024 | Novo Nordisk agreed to acquire Cardior Pharmaceuticals GmbH for up to EUR 1.025 billion, including upfront and milestone-contingent payments, to secure its lead compound CDR132L in phase 2 for treating heart failure, marking its strategic entry into the cardiovascular area with closing expected in Q2 2024. |
Forma Therapeutics, Inc. | 2022 | The acquisition of Forma Therapeutics, Inc. for USD 1.1 billion (at USD 20 per share in cash) was completed via a tender offer and merger, aligning with Novo Nordisk’s strategy to expand its pipeline in sickle cell and rare blood disorders through its lead candidate, etavopivat. |
Dicerna Pharmaceuticals, Inc. | 2021 | Novo Nordisk acquired Dicerna Pharmaceuticals, Inc. through a cash tender offer at $38.25 per share (totaling approximately $3.3 billion) to gain access to its proprietary RNAi platforms, including GalXC™ technologies, supporting its entry into therapeutic areas such as NASH, diabetes, and rare diseases; the deal was primarily debt-financed. |
Recent press releases and 8-K filings for NVO.
- Novo Nordisk re-merged its research and development organizations in August to enhance synergies and accelerate pipeline progression, maintaining a core strategic focus on diabetes and obesity and related comorbidities.
- The company reported new data for semaglutide showing 21% weight loss in obesity, with EU regulatory approval filed and US filing planned for Q4 2025. Oral semaglutide for obesity demonstrated 17% weight loss and is slated for US launch in Q1 2026.
- Key pipeline updates include upcoming readouts for CagriSema (type 2 diabetes) and Amiglutide (obesity, with phase 1 data showing 24.4% weight loss), alongside the initiation of phase 3 for Cagrilentide (offering 12% weight loss with fewer GI side effects).
- Novo Nordisk emphasized semaglutide's significant 26% cardiovascular risk reduction in diabetes, noting its numerical superiority compared to other GLP-1 therapies and that weight loss explains less than 30% of this benefit.
- The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label in the EU, making it the first and only oral GLP-1 RA with a proven cardiovascular benefit for type 2 diabetes.
- This approval is based on results from the SOUL clinical trial, which demonstrated a 14% reduction in cardiovascular death, heart attack, and stroke (MACE) versus placebo.
- New results from the SOUL trial, including a significant reduction in hospitalizations, are scheduled to be presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting this week.
- A decision is anticipated later this year in the US for a label extension for the cardiovascular indication for Rybelsus®, and a decision for an oral 25 mg semaglutide (Wegovy®) for chronic weight management in the US is expected at the turn of this year.
- A class action lawsuit has been filed against Novo Nordisk A/S (NVO) on behalf of investors who purchased securities between May 7, 2025, and July 28, 2025.
- The lawsuit alleges that Novo Nordisk made materially false and misleading statements and concealed adverse facts regarding its growth potential and ability to penetrate the GLP-1 market.
- This legal action follows Novo Nordisk's announcement on July 29, 2025, that it was lowering its sales and profit outlook for the second half of 2025, attributing it to the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition.
- Following this news, Novo Nordisk's stock price declined by approximately 21.83% on July 29, 2025, falling from $69.00 to $53.94 per share.
- Investors have until September 30, 2025, to apply to be appointed as lead plaintiff in the lawsuit.
- Faruqi & Faruqi, LLP is investigating potential claims and has filed a federal securities class action against Novo Nordisk A/S (NVO).
- The complaint alleges that Novo made false and/or misleading statements and/or failed to disclose the true state of its growth potential, particularly regarding the compounded GLP-1 market and its ability to penetrate said markets.
- On July 29, 2025, Novo announced it was lowering its sales and profit outlook for the second half of 2025 for Wegovy and Ozempic, citing factors such as the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition.
- Following this news, Novo's stock price declined dramatically on July 29, 2025, falling from $69.00 per share on July 28, 2025, to $53.94 per share, a decline of about 21.83%.
- Investors who purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025, are encouraged to contact Faruqi & Faruqi, LLP, with a deadline of September 30, 2025, to seek the role of lead plaintiff.
- Novo Nordisk's weight-loss drug Wegovy demonstrated a significant 57% reduction in the risk of heart attack, stroke, or death compared to Eli Lilly’s competing drugs in a real-world observational study involving over 21,000 overweight and obese patients with cardiovascular disease but without diabetes.
- The study indicated that only 0.1% of patients treated with Wegovy experienced major adverse cardiovascular events, compared to 0.4% in the tirzepatide group, reinforcing semaglutide's unique cardiovascular benefits.
- Financial analysts anticipate a potential rise in Novo Nordisk’s stock value, with GuruFocus estimating a 178.2% upside to a fair market value of $157.07, as these findings may help the company regain market share in the growing weight-loss drug sector.
- Despite these positive results, Novo Nordisk is facing increased competition and has implemented a global hiring freeze for non-critical roles, which has contributed to Denmark lowering its 2025 economic growth forecast.
- Faruqi & Faruqi, LLP is investigating potential claims against Novo Nordisk A/S (NYSE: NOVO), and a federal securities class action has been filed.
- The lawsuit alleges the company made false and/or misleading statements regarding its growth potential, specifically concerning the impact of compounded GLP-1s and market penetration.
- This action follows Novo's July 29, 2025 announcement to lower its sales and profit outlook for the second half of 2025, attributing it to persistent use of compounded GLP-1s, slower market expansion, and competition.
- Following this news, Novo's stock price declined by approximately 21.83% on July 29, 2025, dropping from $69.00 to $53.94 per share.
- Investors who purchased securities between May 7, 2025, and July 28, 2025, are encouraged to contact the firm, with a lead plaintiff deadline of September 30, 2025.
- Regeneron announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions.
- These submissions include a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement for the EYLEA HD prefilled syringe and a supplemental Biologics License Application seeking approval for the treatment of macular edema following retinal vein occlusion (RVO) and broadening the dosing schedule.
- The FDA extended the review periods because information provided after a recent inspection of a third-party manufacturer, Catalent Indiana LLC, constituted a major amendment to each submission.
- Catalent Indiana LLC was acquired by Novo Nordisk A/S in December 2024, and Novo Nordisk submitted a comprehensive response in early August 2025 to address the FDA's observations.
- Novo Nordisk has instituted a global hiring freeze for non-essential roles.
- This measure follows a significant $70 billion loss in market value in July and a profit warning, prompting the new CEO, Mike Doustdar, to focus on cost-saving.
- The freeze is part of a strategic adjustment to stabilize and strengthen the company's financial position amid increasing competition.
- A class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between April 29, 2025, and June 23, 2025.
- The lawsuit alleges that Hims & Hers engaged in deceptive promotion and sale of "knockoff" versions of Wegovy®, which led to the termination of its collaboration with Novo Nordisk A/S.
- On June 23, 2025, Novo Nordisk A/S announced the termination of its partnership with Hims & Hers, causing Hims & Hers shares to fall more than 34%.
- Investors have until August 25, 2025, to file a lead plaintiff motion in the class action.
- Novo Nordisk has partnered with GoodRx to offer its GLP-1 medications, Ozempic and Wegovy, at a discounted cash price of $499 per month for self-paying patients.
- This collaboration aims to increase accessibility for patients lacking adequate insurance coverage, making these FDA-approved treatments available at over 70,000 retail pharmacies nationwide.
- GoodRx's CEO emphasized providing only legally approved options, explicitly rejecting compounded versions, which differentiates their approach from other telehealth platforms.
- The announcement led to a 25% share price increase for GoodRx, reflecting investor optimism about the expanded market reach.